Evidence map›Paper›PMID 30758886›Full record

ArticleJournal of clinical apheresis2019

Therapeutic effect of double plasma molecular adsorption system and sequential half-dose plasma exchange in patients with HBV-related acute-on-chronic liver failure.

Jia Yao, Shuang Li, Li Zhou, Lei Luo, Lili Yuan, Zhongping Duan, Jun Xu, Yu Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical apheresis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. [Guidelines for the diagnosis and treatment of acute-on-chronic liver failure (2025 version)].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2025
    Guideline
  2. [Meta-analysis of the therapeutic value of plasma exchange simple or combined with dual plasma molecular adsorption system for liver failure].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2022
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Extended Double Plasma Molecular Adsorption Sessions and Bilirubin Clearance: A Case Report.Hemodialysis international. International Symposium on Home Hemodialysis · 2026
    Article
  7. Observational
  8. Review
  9. Review
  10. Observational
  11. Article
  12. Article
  13. Article
  14. Review
  15. Observational
  16. Observational
  17. Article
  18. Article
  19. Article
  20. [Clinical application and technical operation specification of dual plasma molecular adsorption system].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jia YaoGastroenterology Department，General Surgery Department, Shanxi Dayi Hospital, Taiyuan, China.
Shuang LiDifficult & Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Li ZhouDifficult & Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Lei LuoThe First Clinical Medical School, Lanzhou University, Lanzhou, China.
Lili YuanGastroenterology Department，General Surgery Department, Shanxi Dayi Hospital, Taiyuan, China.
Zhongping DuanDifficult & Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Jun XuGastroenterology Department，General Surgery Department, Shanxi Dayi Hospital, Taiyuan, China.
Yu ChenDifficult & Complicated Liver Diseases and Artificial Liver Center, Beijing Youan Hospital, Capital Medical University, Beijing, China.

Funding

"Beijing Municipal Administration of Hospitals" Ascent Plan DFL20151601Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support ZYLX201806National Key R&D Program of China 2017YFA0103000National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment" 2012ZX10002004-006National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment" 2017ZX10201201National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment" 2017ZX10202203-006-001National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment" 2017ZX10203201-005National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Prevention and Treatment" 2017ZX10302201-004-002Natural Science Foundation of China 81600561Shanxi Province 136 Revitalization Medical Engineering
6 · The paper itself

Abstract

objectiveThe artificial liver support system (ALSS) is used frequently as a first-line treatment for hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). This study aims to compare the therapeutic efficacy of double plasma molecular adsorption system (DPMAS) with sequential half-dose plasma exchange (PE) (DPMAS+PE) and full-dose PE in patients with HBV-ACLF.

methodsA total of 131 hospitalized patients who were diagnosed with HBV-ACLF and underwent DPMAS+PE or PE were retrospectively analyzed. According to the treatment methods used, they were divided into PE group (n = 77) and DPMAS+PE group (n = 54). The main evaluation indexes included the change of liver function and the 28-days liver transplant-free survival rates after the different treatments.

resultsThere were no significant differences on severity of illness between PE group and DPMAS+PE group (P > 0.05). The total bilirubin (TBIL) levels immediately after treatment, and at 24 and 72 hours after treatment were markedly decreased in DPMAS+PE group than that in PE group (52.3 ± 9.4% vs 42.3 ± 7.2%, P < 0.05; 24.2 ± 10.0% vs 13.5 ± 13.0%, P < 0.05; 24.8 ± 13.1% vs 14.9 ± 14.9%, P < 0.05; respectively). The 28-days survival rates was 62.3% and 72.2% in PE and DPMAS+PE groups (P = 0.146). Furthermore, the 28-days survival rates were significantly higher in DPMAS+PE group than that in PE group (57.4% vs 41.7%, P = 0.043) in the intermediate-advanced stage patients.

conclusionCompared with PE alone, DPMAS+PE might more effectively improve temporary TBIL in ACLF patients, and improve the 28-days survival rates in HBV-ACLF patients with intermediate-advanced stage. Therefore, DPMAS+PE may be an available ALSS treatment for HBV-ACLF patients.

Indexed as

AdsorptionHepatitis B virusAcute-On-Chronic Liver FailureBilirubinFemaleHumansLiverLiver TransplantationMaleMiddle AgedPlasma ExchangeRetrospective StudiesSurvival RateTreatment OutcomeBilirubinacute-on-chronic liver failureartificial liver supportdouble plasma molecular absorption systemplasma exchange

Identifiers

PMID30758886
PMCPMC6767528

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.